


Surrogate *in vitro* activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens

Supplementary Material



Supplemental Fig S1: Functional activation of CD33+ (myeloid) PBMC during the first 2 days of culture: **A.** IL-12p70 production by CD33+ PBMC is strongly impacted by culture media. Cultures as in Fig 1A, comparing impacts of media upon danger signal-induced IL-12p70 production. Complete RPMI 1640 supplemented with 10% heat-deactivated human AB serum was compared to RPMI 1640 10% FCS, and to Gibco macrophage SFM, all groups receiving GM-CSF (GM) and IL-4 on d0 and various danger signals on d1 for a d2 harvest. Representative of two biological replicates. **B.** Culture as in Fig 1A, comparing impacts of 40 ng/ml GM and/or 20ng/ml IL-4 upon danger signal-induced IL-12p70 production in RPMI 1640 with 10% human AB serum. Representative of two biological replicates. Note that IL-12p70 production is shown in log scale. **C.** d2 PBMC stained for surface CD33 and intracellular IL-12p70 demonstrating that IL-12p70 production was confined to the CD33+ myeloid fraction (green subpopulation). Right upper quadrants (RUQ) show % of CD33+ cells that are also IL-12p70+, with background isotype control staining subtracted. **D.** d2 PBMC stained for surface CD33 and surface CD11c, demonstrating that treatment with GM and/or TLR agonists resulted in generalized myeloid cell expression of CD11c (blue subpopulation). RUQ shows % of CD33+ cells that are also CD11c+, with background isotype control staining subtracted. Representative of three biological replicates.

Supplemental Table S1: Calculations for regression analyses in Figure 2


- CD4 Linear Regression
 - $R^2 = 0.84244$, Adjusted $R^2 = 0.77491$
 - ANOVA: Test of Strength of Multiple Linear Regression, If valid model, then $p < 0.02$
 - $p = 0.00613$, so valid model
 - Which Dependent Variable Is Significantly Associated With Response
 - IL2, $p = 0.37771$
 - **IL7, $p = 0.00185$**
 - IL15, $p = 0.35285$
 - IL21, $p = 0.56173$

- CD8 Linear Regression
 - $R^2 = 0.80289$, Adjusted $R^2 = 0.71841$
 - ANOVA: Test of Strength of Multiple Linear Regression, If valid model, then $p < 0.02$
 - $p = 0.01295$, so valid model
 - Which Dependent Variable Is Significantly Associated With Response
 - IL2, $p = 0.58893$
 - **IL7, $p = 0.00572$**
 - IL15, $p = 0.44131$
 - IL21, $p = 0.79968$


- Fold Expansion Linear Regression
 - $R^2 = 0.9034$, Adjusted $R^2 = 0.862$
 - ANOVA: Test of Strength of Multiple Linear Regression, If valid model, then $p < 0.02$
 - $p = 0.00117$, so valid model
 - Which Dependent Variable Is Significantly Associated With Response
 - IL2, $p = 0.53234$
 - **IL7, $p = 0.00406$**
 - IL15, $p = 0.35856$
 - IL21, $p = 0.31246$

Supplemental Table S2: 29 HLA-DR haplotypes encompass nearly 90% of individuals. Peptide regions with clusters of embedded 15-17mers displaying high affinity for these haplotypes are designated as promisingly promiscuous “hot spots” for MHC Class II binding.

Supplemental Table 2: Identification of HLA-DR Alleles Across Races and Ethnicities							
DRB1 Alleles	African American Frequency	Caucasian Frequency	Chinese Frequency	Hispanic Frequency	Indian Frequency	Japanese Frequency	Korean Frequency
0101	2.65%	8.60%	0.93%	4.33%	3.21%	5.84%	5.78%
0102	3.92%	1.38%	0.07%	3.32%	0.13%	0.06%	0.02%
0301	6.99%	12.16%	6.81%	6.95%	7.46%	0.68%	2.20%
0302	6.31%	0.03%	0.00%	0.50%	0.01%	0.01%	0.00%
0401	2.02%	8.78%	0.51%	1.81%	0.90%	1.15%	0.78%
0403	0.17%	0.79%	2.31%	1.84%	5.27%	2.43%	2.57%
0404	0.82%	3.88%	0.88%	5.76%	2.01%	0.32%	1.39%
0405	1.53%	0.67%	6.12%	2.22%	0.75%	14.72%	8.94%
0407	0.39%	1.12%	0.08%	7.47%	0.13%	0.64%	0.44%
0701	10.11%	13.42%	5.31%	9.61%	16.95%	0.94%	7.15%
0802	0.09%	0.08%	0.55%	9.64%	0.51%	4.34%	2.50%
0803	0.04%	0.24%	6.80%	0.27%	0.71%	7.44%	7.62%
0804	5.42%	0.20%	0.01%	0.68%	0.08%	0.02%	0.00%
0901	2.97%	1.03%	15.54%	0.82%	0.94%	13.87%	9.67%
1001	1.92%	0.85%	1.34%	1.30%	6.28%	0.40%	1.70%
1101	8.54%	5.56%	6.26%	3.55%	5.98%	2.58%	4.73%
1104	0.58%	2.95%	0.25%	3.25%	1.97%	0.12%	0.07%
1201	3.82%	1.64%	3.42%	0.91%	0.60%	3.75%	4.83%
1202	0.29%	0.02%	11.50%	0.15%	2.99%	1.71%	3.45%
1301	5.42%	5.63%	0.78%	3.72%	6.73%	0.76%	1.73%
1302	7.30%	4.88%	2.42%	3.50%	3.37%	5.75%	8.62%
1303	3.26%	1.09%	0.02%	1.06%	0.13%	0.04%	0.01%
1401	1.86%	2.61%	3.33%	1.84%	1.13%	3.01%	2.68%
1404	0.05%	0.07%	0.51%	0.03%	7.13%	0.02%	0.06%
1406	0.01%	0.02%	0.02%	4.27%	0.05%	1.42%	0.68%
1501	2.82%	13.46%	10.12%	6.43%	9.02%	8.67%	7.94%
1502	0.23%	0.72%	2.66%	1.17%	10.73%	9.67%	3.18%
1503	11.66%	0.05%	0.00%	0.58%	0.02%	0.01%	0.00%
1602	1.38%	0.15%	4.35%	2.47%	0.67%	0.67%	0.99%
Total Coverage	92.6%	92.1%	92.9%	89.4%	95.8%	91.0%	89.7%




Supplemental Fig S2: Phenotype and functional analyses of culture-expanded PBMC-derived T-cells. CAN-driven, GM+R848+LPS conditioned PBMC-derived T-cell cultures were restimulated with CAN-pulsed PBMC in an ICC assay on d16. Cultures were run as described in Fig 1B-D. **A.** Co-expression of functional markers. CD4⁺ T-cells staining positively for intracellular IFN γ upon CAN restimulation (blue subpopulation) were co-analyzed for CD28, CD56, and CCR7. It was observed that >90% of IFN γ ⁺ cells costained for CD28 and <5% for CD56. Subsets of both CCR7⁺ and CCR7⁻ IFN γ ⁺ cells were observed, consistent with a mix of central memory and memory effector T-cells. **B.** CD4⁺ T-cells reexposed to CAN were simultaneously stained intracellularly for IFN γ , IL-2 and IL-17 using distinctive fluorochrome conjugates. Percentages of cells staining positivity for at least one of these cytokines were enumerated. This is representative of 3 experiments examining simultaneous T-cell production of multiple cytokines.




Supplemental Fig S3: CD28, PD1, CTLA4 and Foxp3 expression on T-cells at end of culture. Multicolored FACS analysis of CMVpp65-driven, PBMC-derived T-cell cultures run from a healthy donor and a patient with metastatic breast cancer (cultures performed as in **Fig 1B** “GM+R848+LPS” group), showing T-cell co-expression of CD28, PD1, CTLA4 and Foxp3 (see Methods for staining details). Analyses are gated to show CD4+ or CD8+ cells. Numbers shown in RUQs indicate the % of CD4+ or CD8+ T-cells co-expressing the molecules of interest. Representative of 3 biological replicates.

Healthy Donor

Cancer Patient



Supplemental Fig S4: Foxp3, Helios, LAP and GARP co-expression on T-cells at end of culture. Multicolored FACS analysis of CMVpp65-driven, PBMC-derived T-cell cultures run from a healthy donor and a patient with metastatic breast cancer (cultures run as in **Fig 1B**, see Methods for staining details). Analyses are gated to show CD4⁺ or CD8⁺ cells, with numbers in each right upper quadrant (RUQ) indicating the % of total CD4⁺ or CD8⁺ T-cells within the quadrant co-expressing the molecule(s) of interest. Representative of 3 biological replicates.



Supplemental Fig S5: T-cells cultured from unfractionated PBMC can be effectively driven by cocktails containing multiple antigenic peptides, and can be effectively expanded in scaled-up culture vessels. A. PBMC were obtained by venipuncture from a patient with advanced breast cancer. With cultures performed as in **Fig 1B** “GM+R848+LPS” group, PBMC were exposed on culture d1 to a cocktail of SEA1, SEA2 and CMV peptides. Prior experiments demonstrated that while pulsing individual peptides at 50 $\mu\text{g}/\text{ml}$ was most effective for driving T-cell sensitization, combining the peptides in a cocktail was most effective when only 10 $\mu\text{g}/\text{ml}$ of each peptide was added (not shown). Plots show % of CD4+ or CD8+ T-cells producing IFN γ at culture end when restimulated with freshly thawed autologous PBMC either unpulsed (UP) or pulsed with the individual peptides. The ability to employ this culture method to successfully drive MUC1- and/or HER2-specific T-cells, both CD4+ and CD8+, was observed for four out of four patients at various stages of breast cancer. **B.** PBMC from a healthy donor cultured as in **Fig 1B**, exposed to a cocktail of SEA1+SEA2 peptides during culture in either 24 well cluster plates or scaled up in G-Rex 100M (1-liter) culture vessels. Panels show frequencies of SEA-specific CD4+ (**B1**) and CD8+ (**B2**) T-cells when assayed on day 19 of culture, as well as the fold increase in absolute numbers (gross expansion) (**B3**). This is representative of three biological replicates.